Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.

doi:10.1177/1060028020914274

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.

The Annals of pharmacotherapy - 1 Oct 2020

Stevens Debra, Claborn Melanie K, Gildon Brooke L, Kessler Tiffany L, Walker Cheri

Abstract excerpt

OBJECTIVE: To review the efficacy and safety of onasemnogene abeparvovec-xioi (Zolgensma) in the treatment of spinal muscular atrophy (SMA). DATA SOURCES: An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to December 2019) was completed using the terms onasemnogene, AVXS-101, and spinal muscular atrophy. Manufacturer prescribing information, article bibliographies, and data from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Drug Approval
Share to Genetic Therapy
Share to Recombinant Fusion Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Spinal Muscular Atrophies of Childhood

Share to Survival of Motor Neuron 1 Protein

Share to United States

Share to United States Food and Drug Administration

Source

Open in PubMed

Identifiers

PMID: 32204605
DOI: 10.1177/1060028020914274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.